Industry & Policy News

[AAMC] The laureate discusses the groundbreaking work that led to COVID-19 vaccines, why he persisted with RNA research despite repeated setbacks, and the value of scientists working in-person.

[NUS News] Researchers from Duke-NUS Medical School have discovered a new vaccine candidate that can be delivered through the nose in the form of a spray that promises better and longer-lasting immunity against COVID-19 compared to the conventional COVID-19 vaccine administered subcutaneously.

[Sasktoday] University of Saskatchewan (USask) graduate student Ethan Jansen is on a mission to help those affected by emerging global viruses and has joined a team of Canadian researchers leading the charge to discover more about the long-term effects of COVID-19.

[EurekAlert] A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.

[Takeda] Takeda announced that the FDA approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

[PharmTech.com] Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by Novartis. Calypso’s shareholders are set to receive an upfront payment of $250 million and are eligible to receive development milestones of up to $175 million.